Market Research Logo

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Pipeline Insight, 2019

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Pipeline Insight, 2019

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy (Natural killer (NK) cell leukemia)

Overview:
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Pipeline Insight, 2019 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy pipeline landscape is provided which includes the disease overview and Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy treatment guidelines. The assessment part of the report embraces, in depth Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Understanding
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a historically rare, highly aggressive disease for which there are no approved or standard therapies, and median overall survival (OS) reported by most groups for adult patients is eight to 14 months, despite use of multiagent cytotoxic chemotherapy programs as used in acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), or lymphomas. BPDCN most commonly manifests as cutaneous lesions with or without bone marrow involvement and leukemic dissemination. BPDCN affects patients’ skin, bone marrow, lymph nodes and blood. Since it affects almost every single part of the body, blastic plasmacytoid dendritic cell neoplasm symptoms can be difficult to recognize, making the disease difficult to diagnose. Practically every BPDCN patient gets skin lesions. They often appear on, arms, legs, face and neck, but can show up anywhere on the body. In addition, the disease can cause swollen lymph nodes and a swollen spleen that can lead to stomach pain. So it combines features of leukemia, lymphoma and skin cancer.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy pipeline report covers 6+ companies. Some of the key players include AbbVie (Venetoclax), ImmunoGen (IMGN632), Xencor (XmAb14045) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Analytical Perspective by DelveInsight
• In-depth Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
• The Blastic plasmacytoid dendritic cell neoplasm malignancy report provides an overview of therapeutic pipeline activity for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Blastic plasmacytoid dendritic cell neoplasm malignancy therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Blastic plasmacytoid dendritic cell neoplasm malignancy Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Blastic plasmacytoid dendritic cell neoplasm malignancy
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy to formulate effective R&D strategies
• Assess challenges and opportunities that influence Blastic plasmacytoid dendritic cell neoplasm malignancy R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Blastic plasmacytoid dendritic cell neoplasm malignancy in licensing and out licensing strategies by identifying prospective partners with progressing projects for Blastic plasmacytoid dendritic cell neoplasm malignancy to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugsPlease Note: The report will be delivered in 2-3 business days upon order confirmation.


1. Report Introduction
2. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) (Natural killer (NK) cell leukemia)
2.1. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Disease Overview
2.2. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) History
2.3. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Symptoms
2.4. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Causes
2.5. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Pathophysiology
2.6. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Diagnosis
2.6.1. Diagnostic Guidelines
3. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Current Treatment Patterns
3.1. Treatment Guidelines
4. Blastic plasmacytoid dendritic cell neoplasm (BPDCN)- DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Blastic plasmacytoid dendritic cell neoplasm companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Blastic plasmacytoid dendritic cell neoplasm Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Blastic plasmacytoid dendritic cell neoplasm Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. Blastic plasmacytoid dendritic cell neoplasm Pipeline Therapeutics
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. Blastic plasmacytoid dendritic cell neoplasm -Products Analysis
6.1. Product Profiles
6.1.1. Venetoclax : AbbVie
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. IMGN632: ImmunoGen
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
6.1.3. XmAb14045: Xencor
6.1.3.1. Product Description
6.1.3.1.1. Product Overview
6.1.3.1.2. Mechanism of Action
6.1.3.2. Research and Development
6.1.3.2.1. Clinical Studies
6.1.3.2.1.1. Detailed Study Description
6.1.3.2.1.2. Study Results
6.1.3.2.1.3. Clinical Trials: Tabular View
6.1.3.3. Product Development Activities
6.1.3.3.1. Tabulated Product Summary
6.1.3.3.1.1. General Description Table
To be continued in the report…………………………
7. Recent Technologies
8. Blastic plasmacytoid dendritic cell neoplasm Key Companies
8.1. Stemline Therapeutics
8.2. ImmunoGen
8.3. Cellectis
8.4. Mustang Bio
8.5. AbbVie
8.6. Xencor
9. Blastic plasmacytoid dendritic cell neoplasm Key Products
9.1. Tagraxofusp
9.2. IMGN 632
9.3. UCART 123
9.4. MB 102
9.5. Venetoclax
9.6. XmAb14045
10. Dormant and Discontinued Products
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. Blastic plasmacytoid dendritic cell neoplasm - Unmet Needs
12. Blastic plasmacytoid dendritic cell neoplasm - Future Perspectives
13. Appendix
14. Report Methodology
14.1. Secondary Research
14.2. Expert Panel Validation
TABLE 1 Diagnostic Guidelines
TABLE 2 Treatment Guidelines
TABLE 3 Assessment Summary
TABLE 4 Company-Company Collaborations (Licensing / Partnering) Analysis
TABLE 5 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Acquisition Analysis
TABLE 6 Assessment by Phase of Development
TABLE 7 Assessment by Product Type (Mono / Combination)
TABLE 8 Assessment by Stage and Product Type
TABLE 9 Assessment by Route of Administration
TABLE 10 Assessment by Stage and Route of Administration
TABLE 11 Assessment by Molecule Type
TABLE 12 Assessment by Stage and Molecule Type
TABLE 13 Assessment by MOA
TABLE 14 Assessment by Stage and MOA
TABLE 15 Late Stage Products (Phase-III)
TABLE 16 Mid Stage Products (Phase-II)
TABLE 17 Early Stage Products (Phase-I)
TABLE 18 Pre-clinical and Discovery Stage Products
TABLE 19 Inactive Products
TABLE 20 Dormant Products
TABLE 21 Discontinued Products
Figure 1 Disease Overview
Figure 2 History
Figure 3 Symptoms
Figure 4 Causes
Figure 5 Pathophysiology
Figure 6 Diagnostic Guidelines
Figure 7 Treatment Guidelines
Figure 8 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9 Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Acquisition Analysis
Figure 11 Assessment by Phase of Development
Figure 12 Assessment by Product Type (Mono / Combination)
Figure 13 Assessment by Stage and Product Type
Figure 14 Assessment by Route of Administration
Figure 15 Assessment by Stage and Route of Administration
Figure 16 Assessment by Molecule Type
Figure 17 Assessment by Stage and Molecule Type
Figure 18 Assessment by MOA
Figure 19 Assessment by Stage and MOA
Figure 20 Late Stage Products (Phase-III)
Figure 21 Mid Stage Products (Phase-II)
Figure 22 Early Stage Products (Phase-I)
Figure 23 Pre-clinical and Discovery Stage Products
Figure 24 Inactive Products
Figure 25 Dormant Products
Figure 26 Discontinued Products
Figure 27 Unmet Needs

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report